GlaxoSmithKline PLC ADR (GSK) carries a ŷRobot AI score of 61 out of 100. The model's fair value estimate is $52.92, 7.2% above the last close of $49.36. The chart signal reads Buy.
| Metric | GSK |
|---|---|
| AI score | 61 / 100 |
| Chart signal | Buy |
| Fair value estimate | $52.92 |
| Upside to fair value | 7.2% |
| Previous close | $49.36 |
| P/E | 15.88 |
| Price / sales | 3.03 |
| Market cap | $98.62B |
| EPS | 3.20 |
| Revenue growth | 3.6% |
| 1-year price change | 2.5% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 29, 2026, ŷRobot's fair-value model estimates GlaxoSmithKline PLC ADR (GSK) at $52.92 against a last close of $49.36, implying 7.2% upside to the model's estimate.
The chart-signal model classifies GSK as Bullish as of Sep 29, 2026, with a signal score of 0.20 on a -1 to 1 scale.
GSK scores 61 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
GSK trades at 15.9 times earnings and 3.0 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for GSK reads +0.2% at 30 days, +1.7% at 90 days, and +2.5% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
GlaxoSmithKline PLC ADR's revenue growth is +3.6% and free-cash-flow growth is -44.7% on the latest reported figures.
GSK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.